About Ouro Medicines
Ouro Medicines is a company based in San Francisco (United States) founded in 2024 was acquired by Gilead in March 2026.. Ouro Medicines has raised $120 million across 1 funding round from investors including Gilead, UPMC and TPG. Ouro Medicines offers products and services including OM336 and T Cell Engagers. Ouro Medicines operates in a competitive market with competitors including Moderna, BeiGene, Biogen, Incyte and ADMA Biologics, among others.
- Headquarter San Francisco, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ouro Medicines
Ouro Medicines offers a comprehensive portfolio of products and services, including OM336 and T Cell Engagers. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Drug candidate for resetting immune systems in immune-mediated diseases
Modality for depleting proinflammatory cells to achieve immune reset
Unlock access to complete
Unlock access to complete
Funding Insights of Ouro Medicines
Ouro Medicines has successfully raised a total of $120M through 1 strategic funding round. The most recent funding activity was a Series A round of $120 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $120.0M
-
First Round
First Round
(10 Jan 2025)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2025 | Amount | Series A - Ouro Medicines | Valuation | TPG , New Enterprise Associates |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ouro Medicines
Ouro Medicines has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Gilead, UPMC and TPG. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Fund of funds focused on pre-seed and seed-stage companies
|
Founded Year | Domain | Location | |
|
Venture capital investments are offered to startups by NEA.
|
Founded Year | Domain | Location | |
|
Venture capital and growth equity firm providing investments and resources to entrepreneurs in various sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ouro Medicines
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Ouro Medicines
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ouro Medicines Comparisons
Competitors of Ouro Medicines
Ouro Medicines operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Biogen, Incyte and ADMA Biologics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| domain | founded_year | HQ Location |
Antibodies are developed for treating cancer, eye, and inflammatory diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Ouro Medicines
When was Ouro Medicines founded?
Ouro Medicines was founded in 2024 and raised its 1st funding round 1 year after it was founded.
Where is Ouro Medicines located?
Ouro Medicines is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Who is the current CEO of Ouro Medicines?
Jaideep Dudani is the current CEO of Ouro Medicines.
Is Ouro Medicines a funded company?
Ouro Medicines is a funded company, having raised a total of $120M across 1 funding round to date. The company's 1st funding round was a Series A of $120M, raised on Jan 10, 2025.
What does Ouro Medicines do?
Ouro Medicines was founded in 2024 and is based in San Francisco, United States. Focus is placed on the biotechnology sector, where therapeutics for chronic immune-mediated diseases are developed. Operations center on advancing treatments that target B cell biology. A lead candidate, OM336, is pursued for multiple myeloma and related immune conditions. The companys work supports patients through innovative therapeutic approaches in the immunology field.
Who are the top competitors of Ouro Medicines?
Ouro Medicines's top competitors include Moderna, BeiGene and ADMA Biologics.
What products or services does Ouro Medicines offer?
Ouro Medicines offers OM336 and T Cell Engagers.
Who are Ouro Medicines's investors?
Ouro Medicines has 9 investors. Key investors include Gilead, UPMC, TPG, Norwest Venture Partners, and GSK.